Piperidine → HCID 22015611, 화합물

HRID 8372

반응식

HRID 8372 반응식
Br.Cl[CH2:3][CH2:4][CH2:5][O:6][C:7]1[CH:12]=[CH:11][C:10]([C:13]2[N:14]=[C:15]3[CH:20]=[C:19]([CH3:21])[CH:18]=[CH:17][N:16]3[CH:22]=2)=[CH:9][C:8]=1[O:23][CH3:24].[NH:25]1[CH2:30][CH2:29][CH2:28][CH2:27][CH2:26]1>>[N:25]1([CH2:3][CH2:4][CH2:5][O:6][C:7]2[CH:12]=[CH:11][C:10]([C:13]3[N:14]=[C:15]4[CH:20]=[C:19]([CH3:21])[CH:18]=[CH:17][N:16]4[CH:22]=3)=[CH:9][C:8]=2[O:23][CH3:24])[CH2:30][CH2:29][CH2:28][CH2:27][CH2:26]1

참가 물질

3

반응물 2

HCID 8082PiperidineHCID 220155982-(4'-Chloropropoxy-3'-methoxyphenyl)-7-methylimidazo[1,2-a]pyridine hydrobromide

생성물 1

HCID 22015611HCID 22015611, 화합물

실험 절차

The product of Step C (184 mg) and piperidine (1.5 mL) were heated at 100° C. for 4 hours. The reaction was cooled to ambient temperature and partitioned between ethyl acetate (10 mL) and saturated sodium bicarbonate solution (10 mL). The aqueous portion was extracted twice with additional ethyl acetate (10 mL) and once with dichloromethane (10 mL). The organic portions were combined, washed with brine, and evaporated. The residue was purified via silica gel chromatography (dichloromethane/2M ammonia in methanol) to give the title compound (150 mg). 1H-NMR (CD3OD) δ 8.17 (d, J=7.0 Hz, 1H), 7.93 (s, 1H), 7.50 (d, J=2.0 Hz, 1H), 7.38 (dd, J=8.0 Hz, J=2.0 Hz, 1H), 7.26 (s, 1H), 6.93 (d, J=8.0 Hz, 1H), 6.68 (dd, J=7.0 Hz, J=1.5 Hz, 1H), 4.00 (t, J=6.0 Hz, 2H), 3.91 (s, 3H), 2.56 (m, 3H), 2.48 (br. s, 3H), 2.38 (s, 3H), 1.98 (m, 2H), 1.60 (m, 4H), 1.47 (m, 2H)

후처리

  1. custompartitioned between ethyl acetate (10 mL) and saturated sodium bicarbonate solution (10 mL)
  2. extractionThe aqueous portion was extracted twice with additional ethyl acetate (10 mL) and once with dichloromethane (10 mL)
  3. washwashed with brine
  4. customevaporated
  5. customThe residue was purified via silica gel chromatography (dichloromethane/2M ammonia in methanol)

출처 및 근거

ORD 기록
ord-66426ac545ed4e13990d7efe19725d70
출처 데이터셋
uspto-grants-2006_08
특허 번호
US07087757B2

연결된 노트

불러오는 중…